Brown, Lisle/Cummings’s Charles River Laboratories CRL Stock Holding History

Brown, Lisle/Cummings’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.21K	Buy	+7	New	+$1.3K	﹤0.01%	905

Other funds holding CRL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Brown, Lisle/Cummings's CRL Position: Q1 2026 in Review

Brown, Lisle/Cummings opened a new position in Charles River Laboratories (CRL) in Q1 2026: 7 shares worth $1.21K. The stake represents ﹤0.01% of the portfolio and ranks #905 among its holdings.

559 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

Brown, Lisle/Cummings held 7 shares of Charles River Laboratories worth $1.21K as of Q1 2026.
Charles River Laboratories was a new Brown, Lisle/Cummings position in Q1 2026.
Charles River Laboratories made up ﹤0.01% of Brown, Lisle/Cummings's portfolio in Q1 2026, its #905 holding.
559 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q1 2026, filed 20 Apr 2026.